Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608961 | 0.89 | PDE10A (0.35) | STING1PDE10APDE4DPDE4B | |
| SCHEMBL15347806 | 0.70 | GSK3B (0.45) | PDE10APDE4B | |
| SCHEMBL3367365 | 0.68 | COMT (0.32) | — | |
| SCHEMBL14994640 | 0.67 | PDE4B (0.35) | PDE10APDE4DPDE4BDRD4 | |
| SCHEMBL2403696 | 0.65 | ALDH1A1 (0.34) | SMN1; SMN2 | |
| SCHEMBL14994003 | 0.64 | CFTR (0.43) | PDE10APDE4DPDE4BDRD4 | |
| SCHEMBL4983095 | 0.64 | PDE4B (0.42) | PDE10APDE4B | |
| SCHEMBL7388558 | 0.64 | STING1 (0.48) | STING1 | |
| SCHEMBL1608941 | 0.64 | HPGD (0.58) | STING1 | |
| SCHEMBL3367487 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | STING1 4828/4885PDE10A 177/4885PDE4D 433/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | STING1 4840/4885PDE10A 278/4885PDE4D 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.